929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC): Pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study
作者
J. Spicer,Tina Cascone,G. Kar,Yong‐Hua Zheng,J. Blando,T.H. Tan,Maria M W Cheng,Raymond Mager,O. Hamid,Yee Soo-Hoo,P.M. Forde,Walter Weder,M.R. García Campelo,I. Grenga,R. Kumar,L. McGrath